(Q36830104)

16 August 2017

1 reference

title

Hormone-refractory prostate cancer: where are we going? (English)

1 reference

16 August 2017

1 reference

2

Riccardo Autorino

1 reference

16 August 2017

Giuseppe Di Lorenzo

1

1 reference

16 August 2017

William D Figg

series ordinal

3

1 reference

16 August 2017

Sabino De Placido

series ordinal

4

1 reference

16 August 2017

1 January 2007

1 reference

16 August 2017

1 reference

16 August 2017

67

1 reference

16 August 2017

8

1 reference

16 August 2017

1109-1124

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200767080-00002

16 August 2017

0 references

cites work

Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767080-00002

Impact of hospital procedure volume on surgical operation and long-term outcomes in high-risk curatively resected rectal cancer: findings from the Intergroup 0114 Study

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200767080-00002

Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.

21 January 2018

1 reference

12 December 2020

A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer

1 reference

12 December 2020

Phase II Evaluations of Cilengitide in Asymptomatic Patients with Androgen-Independent Prostate Cancer: Scientific Rationale and Study Design

1 reference

12 December 2020

Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma

1 reference

12 December 2020

Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC).

1 reference

12 December 2020

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

1 reference

12 December 2020

Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer

1 reference

12 December 2020

Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy

1 reference

12 December 2020

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

12 December 2020

A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.

1 reference

12 December 2020

Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial

1 reference

12 December 2020

Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer

1 reference

12 December 2020

Hormone-refractory (D3) prostate cancer: refining the concept.

1 reference

12 December 2020

Irofulven demonstrates clinical activity against metastatic hormone-refractory prostate cancer in a phase 2 single-agent trial

1 reference

12 December 2020

Gain of androgen receptor gene copies in primary prostate cancer due to X chromosome polysomy.

1 reference

12 December 2020

Novel agents that target tublin and related elements

1 reference

12 December 2020

Angiogenesis-targeted therapies in prostate cancer

1 reference

12 December 2020

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth

1 reference

12 December 2020

First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?

1 reference

12 December 2020

Chemotherapy in hormone refractory prostate cancer: where do we stand?

1 reference

12 December 2020

Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

12 December 2020

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

12 December 2020

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

12 December 2020

Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer

1 reference

12 December 2020

Cancer statistics, 2006

1 reference

12 December 2020

Phase II Trial of Gemcitabine, Prednisone, and Zoledronic Acid in Pretreated Patients with Hormone Refractory Prostate Cancer

1 reference

12 December 2020

Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer

1 reference

12 December 2020

A study from the EORTC new drug development group: open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer

1 reference

12 December 2020

Phase I studies with the novel nucleoside analog gemcitabine.

1 reference

12 December 2020

Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.

1 reference

12 December 2020

A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer

1 reference

12 December 2020

Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor

1 reference

12 December 2020

The development of androgen-independent prostate cancer

1 reference

12 December 2020

A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer

1 reference

12 December 2020

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

12 December 2020

Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes

1 reference

12 December 2020

A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer

1 reference

12 December 2020

Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.

1 reference

12 December 2020

Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study

1 reference

12 December 2020

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

1 reference

12 December 2020

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

1 reference

12 December 2020

Management of high risk metastatic prostate cancer: the case for novel therapies

1 reference

12 December 2020

Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma

1 reference

12 December 2020

Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells

1 reference

12 December 2020

The use of thalidomide in androgen-independent prostate cancer

1 reference

12 December 2020

1 reference

12 December 2020

Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study

1 reference

12 December 2020

Current indications for chemotherapy in prostate cancer patients.

1 reference

12 December 2020

Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer

1 reference

12 December 2020

Licochalcone-A, a novel flavonoid isolated from licorice root (Glycyrrhiza glabra), causes G2 and late-G1 arrests in androgen-independent PC-3 prostate cancer cells

1 reference

12 December 2020

Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer

1 reference

12 December 2020

Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.

1 reference

12 December 2020

A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer

1 reference

12 December 2020

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators

1 reference

12 December 2020

Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer.

1 reference

12 December 2020

Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial

1 reference

12 December 2020

Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor

1 reference

12 December 2020

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

1 reference

12 December 2020

10.2165/00003495-200767080-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

16 August 2017

0 references

1 reference